2,177 Johnson & Johnson $JNJ Shares Purchased by IFG Advisory LLC

IFG Advisory LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the third quarter, Holdings Channel.com reports. The firm owned 41,755 shares of the company’s stock after buying an additional 2,177 shares during the quarter. IFG Advisory LLC’s holdings in Johnson & Johnson were worth $11,054,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. AlTi Global Inc. boosted its position in Johnson & Johnson by 3.3% in the third quarter. AlTi Global Inc. now owns 57,487 shares of the company’s stock valued at $15,219,000 after buying an additional 1,848 shares in the last quarter. Phoenix Financial Ltd. increased its holdings in shares of Johnson & Johnson by 13.5% during the third quarter. Phoenix Financial Ltd. now owns 53,162 shares of the company’s stock worth $13,804,000 after buying an additional 6,332 shares in the last quarter. Danske Bank A S increased its holdings in shares of Johnson & Johnson by 6.5% during the third quarter. Danske Bank A S now owns 2,210,087 shares of the company’s stock worth $585,098,000 after buying an additional 134,869 shares in the last quarter. Rasp Wealth Solutions LLC increased its holdings in shares of Johnson & Johnson by 8.2% during the third quarter. Rasp Wealth Solutions LLC now owns 2,732 shares of the company’s stock worth $723,000 after buying an additional 207 shares in the last quarter. Finally, MSH Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the 3rd quarter. MSH Capital Advisors LLC now owns 22,979 shares of the company’s stock valued at $6,083,000 after acquiring an additional 415 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Bank of America reissued a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. HSBC increased their target price on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Finally, Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Trading Up 0.8%

Shares of JNJ stock traded up $2.26 during trading hours on Friday, hitting $285.78. 6,279,519 shares of the company’s stock traded hands, compared to its average volume of 7,472,752. The stock’s 50 day simple moving average is $266.97 and its 200 day simple moving average is $249.85. The stock has a market cap of $687.95 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.80 and a beta of 0.22. Johnson & Johnson has a 12 month low of $193.55 and a 12 month high of $288.11. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Latest Johnson & Johnson News

Here’s some of the latest news about JNJ:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 61,669 shares of company stock worth $16,898,386. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.